← back to search

Lei Liu

Harbin Medical University · CN
Area of research
Computational Theory and Mathematics · Molecular Biology
Research interest
Research focused on Drug and Computational biology, with related work in Drug repositioning, Docking (animal), Similarity (geometry). Notable publications include 'Drug repositioning by applying ‘expression profiles’ generated by integrating chemical structure similarity and gene semantic similarity', 'Synthetic Lethality-based Identification of Targets for Anticancer Drugs in the Human Signaling Network', and 'Identification of long-term survival-associated gene in breast cancer'.
h-index
citations
196
works
13
NIH funding
primary concept
email

Recent publications

Integrating Hypoxia Signatures from scRNA-seq and Bulk Transcriptomes for Prognosis Prediction and Precision Therapy in Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma
International Journal of Molecular Sciences 2025cited by 4position: middledoi
Predicting drug synergy using a network propagation inspired machine learning framework
Briefings in Functional Genomics 2024cited by 6position: middledoi
Identifying a survival-associated cell type based on multi-level transcriptome analysis in idiopathic pulmonary fibrosis
Respiratory Research 2024cited by 3position: middledoi
Identification of Warning Transition Points from Hepatitis B to Hepatocellular Carcinoma Based on Mutation Accumulation for the Early Diagnosis and Potential Drug Treatment of HBV‐HCC
Oxidative Medicine and Cellular Longevity 2022cited by 3position: middledoi
Exploring Precise Medication Strategies for OSCC Based on Single-Cell Transcriptome Analysis from a Dynamic Perspective
Cancers 2022cited by 2position: middledoi
Identification of long-term survival-associated gene in breast cancer
Aging 2020cited by 30position: middledoi
Computational drug repositioning based on the relationships between substructure–indication
Briefings in Bioinformatics 2020cited by 15position: middledoi
Synthetic Lethality-based Identification of Targets for Anticancer Drugs in the Human Signaling Network
Scientific Reports 2018cited by 32position: firstdoi
Designing of dual inhibitors for GSK-3β and CDK5: Virtual screening and<i>in vitro</i>biological activities study
Oncotarget 2017cited by 30position: middledoi
Prediction on the risk population of idiosyncratic adverse reactions based on molecular docking with mutant proteins
Oncotarget 2017cited by 4position: middledoi
Large-Scale Analysis of Drug Side Effects via Complex Regulatory Modules Composed of microRNAs, Transcription Factors and Gene Sets
Scientific Reports 2017cited by 1position: middledoi
In silico drug repositioning for the treatment of Alzheimer's disease using molecular docking and gene expression data
RSC Advances 2016cited by 22position: middledoi
Drug repositioning by applying ‘expression profiles’ generated by integrating chemical structure similarity and gene semantic similarity
Molecular BioSystems 2014cited by 44position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Xiujie Chen · Sun Yat-sen University Cancer Center11 papers (2014–2025)Denan Zhang · Ningbo University7 papers (2016–2024)Hongbo Xie · Nanchang University6 papers (2016–2024)Qing Jin · Virginia Tech6 papers (2016–2024)Qingkang Meng · Harbin Medical University3 papers (2022–2024)Kehui Ke · Harbin Medical University3 papers (2017–2018)Бо Лю · Walmart (United States)2 papers (2016–2017)Fujian Tan · Harbin Medical University2 papers (2014–2017)Hongzhe Ma · Harbin Medical University2 papers (2014–2017)Yiyang Cai · Harbin Medical University2 papers (2020–2024)Meini Yu · Harbin Medical University2 papers (2024–2025)Qiuqi Liu · Harbin Medical University2 papers (2016–2017)Xiangqiong Liu · Harbin Medical University2 papers (2014–2017)Jingbo Yang · Harbin Medical University2 papers (2018–2020)Yunfeng Wang · Center for Life Sciences2 papers (2014–2017)Yun Tong · Nanjing University of Chinese Medicine2 papers (2022–2024)Xiaodong Jia · Harbin Medical University2 papers (2014–2017)Haixia Wen · Texas A&M University2 papers (2016–2017)Ming Hu · Harbin Medical University2 papers (2017–2017)Diwei Huo · Harbin Medical University2 papers (2017–2024)